Prognostic relevance of altered pRb and p53 protein expression in surgically treated non-small cell lung cancer patients

Oncology

Volumn 67, Issue 1, 2004, Pages 60-66

  Dworakowska, Dorota ^a   Jassem, Ewa ^a   Jassem, Jacek ^a   Wiedorn, Klaus Hermann ^b   Boltze, Carsten ^c   Karmoliński, Andrzej ^a   Dworakowski, Rafał ^a   Skokowski, Jan ^a   Jaśkiewicz, Kazimierz ^a   Bosse, Alexander ^b   Czȩstochowska, Eugenia ^a  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

^b Katharinenhospital ^*  (Germany)

^c OTTO VON GUERICKE UNIVERSITY   (Germany)

Author keywords

Non small cell lung cancer; p53 protein; Prognostic value; Rb protein

Indexed keywords

MONOCLONAL ANTIBODY; PROTEIN; PROTEIN P53; PROTEIN PRB; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; LUNG NON SMALL CELL CANCER; LUNG SURGERY; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; MULTIVARIATE ANALYSIS; PATIENT SELECTION; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; STATISTICAL SIGNIFICANCE; TUMOR DIFFERENTIATION;

ANTIBODIES, MONOCLONAL; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETINOBLASTOMA PROTEIN; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 5644271446     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000080287     Document Type: Article

References (35)

1. Knudson AG: Mutation and cancer: Statistical study of retinoblastoma. Proc Natl Acad Sci USA 1971;68:820-823.
2. Horsthemke B, Brandt B, Albrecht B, Passarge E: Deletion in one allele and a rare neutral DNA alteration in the other allele of the RB1 gene in a patient with bilateral retinoblastoma. Am J Med Genet 1992;44:255.
3. Levine AJ, Momand J, Finlay CA: The p53 tumour suppressor gene. Nature 1991;351:453-456.
4. Lane DP: Cancer. p53, guardian of the genome. Nature 1992;358:15-16.
5. Levine AJ: p53, the cellular gatekeeper for growth and division. Cell 1997;88:323-331.
6. Nataraj AJ, Trent JC, Ananthaswamy HN: p53 gene mutations and photocarcinogenesis. Photochem Photobiol 1995;62:218-230.
7. Sherr CJ: Cancer cell cycle. Science 1996;274:1672-1677.
8. Giaccia AJ, Kastan MB: The complexity of p53 modulation: Emerging patterns from divergent signals. Genes Dev 1998;12:2973-2983.
9. Maheswaran S, Englert C, Bennett P, Heinrich G, Haber DA: The WT1 gene product stabilizes p53 and inhibits p53-mediated apoptosis. Genes Dev 1995;9:2143-2156.
10. Morgenbesser SD, Williams BO, Jacks T, De Pinho RA: p53-dependent apoptosis produced by Rb-deficiency in the developing mouse lens. Nature 1994;371:72-74.
11. Mitsudomi T, Hamajima N, Ogawa M, Takahashi T: Prognostic significance of p53 alterations in patients with non-small cell lung cancer: A meta-analysis. Clin Cancer Res 2000;6:4055-4063.
12. Hommura F, Dosaka-Akita H, Kinoshita I, Mishina T, Hiroumi H, Ogura S, Katoh H, Kawakami Y: Predictive value of expression of p16INK4A, retinoblastoma and p53 proteins for the prognosis of non-small-cell lung cancers. Br J Cancer 1999;81:696-701.
13. Xu HJ, Quinlan DC, Davidson AG, Hu SX, Summers CL, Li J, Benedict WF: Altered retinoblastoma protein expression and prognosis in early-stage non-small-cell lung carcinoma. J Natl Cancer Inst 1994,86:695-699.
14. Xu HJ, Cagle PT, Hu SX, Li J, Benedict WF: Altered retinoblastoma and p53 protein status in non-small cell carcinoma of the lung: Potential synergistic effects on prognosis. Clin Cancer Res 1996;2:1169-1176.
15. Lee YC, Chang YL, Luh SP, Lee JM, Chen JS: Significance of p53 and Rb protein expression in surgically treated non-small cell lung cancers. Ann Thorac Surg 1999;68:343-347.
16. Kratzke RA, Greatens TM, Rubins JB, Maddaus MA, Niewoehner DE, Niehans GA, Geradts J: Rb and p16INK4a expression in resected non-small cell lung tumors. Cancer Res 1996;56:3415-3420.
17. Reissmann PT, Koga H, Takahashi R, Figlin RA, Holmes EC, Piantadosi S, Cordon-Cardo C, Slamon DJ: Inactivation of the retinoblastoma susceptibility gene in non-small-cell lung cancer. The Lung Cancer Study Group. Oncogene 1993;8:1913-1919.
18. Betticher DC, White GR, Vonlanthen S, Liu X, Kappeler A, Altermatt HJ, Thatcher N, Heighway J: G1 control gene status is frequently altered in resectable non-small cell lung cancer. Int J Cancer 1997;74:556-562.
19. Dosaka-Akita H, Hu SX, Fujino M, Harada M, Kinoshita I, Xu HJ, Kuzumaki N, Kawakami Y, Benedict WF: Altered retinoblastoma protein expression in nonsmall cell lung cancer: Its synergistic effects with altered ras and p53 protein status on prognosis. Cancer 1997;79:1329-1337.
20. Greenblatt MS, Bennett WP, Hollstein M, Harris CC: Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 1994,54:4855-4878.
21. Sobin LH, Wittekind C: TNM classification of malignant tumors. New York, UICC International Union Against Cancer/ Wiley-Liss, 1997.
22. Jin M, Inoue S, Umemura T, Moriya J, Arakawa M, Nagashima K, Kato H: Cyclin D1, p16 and retinoblastoma gene product expression as a predictor for prognosis in non-small cell lung cancer at stages I and II. Lung Cancer 2001;34: 207-218.
23. Chen JT, Chen YC, Chen CY, Wang YC: Loss of p16 and/or pRb protein expression in NSCLC. An immunohistochemical and prognostic study. Lung Cancer 2001;31:163-170.
24. Nishio M, Koshikawa T, Yatabe Y, Kuroishi T, Suyama M, Nagatake M, Sugiura T, Ariyoshi Y, Mitsudomi T, Takahashi T: Prognostic significance of cyclin D1 and retinoblastoma expression in combination with p53 abnormalities in primary, resected non-small cell lung cancers. Clin Cancer Res 1997;3:1051-1058.
25. Sugio K, Tsukamoto S, Ushijima C, Yamazaki K, Kase S, Yamaguchi M, Ondo K, Yano T, Sugimachi K: Clinical significance of the Rb expression in adenocarcinoma of the lung. Anticancer Res 2001;21:1931-1935.
26. Akin H, Yilmazbayhan D, Kilicaslan Z, Dilege S, Dogan O, Toker A, Kalayci G: Clinical significance of P16INK4A and retinoblastoma proteins in non-small cell lung carcinoma. Lung Cancer 2002;38:253-260.
27. Brambilla E, Moro D, Gazzeri S, Brambilla C: Alterations of expression of Rb, p16(INK4A) and cyclin D1 in non-small cell lung carcinoma and their clinical significance. J Pathol 1999;188:351-360.
28. Carbone DP, Mitsudomi T, Chiba I, Piantadosi S, Rusch V, Nowak JA, McIntire D, Slamon D, Gazdar A, Minna J: p53 immunostaining positivity is associated with reduced survival and is imperfectly correlated with gene mutations in resected non-small cell lung cancer. A preliminary report of LCSG 871. Chest 1994; 106:377S-381S.
29. Ebina M, Steinberg SM, Mulshine JL, Linnoila RI: Relationship of p53 overexpression and upregulation of proliferating cell nuclear antigen with the clinical course of non-small cell lung cancer. Cancer Res 1994;54:2496-2503.
30. Esposito V, Baldi A, De Luca A, Micheli P, Mazzarella G, Baldi F, Caputi M, Giordano A: Prognostic value of p53 in non-small cell lung cancer: Relationship with proliferating cell nuclear antigen and cigarette smoking. Hum Pathol 1997;28:233-237.
31. Pastorino U, Andreola S, Tagliabue E, Pezzella F, Incarbone M, Sozzi G, Buyse M, Menard S, Pierotti M, Rilke F: Immunocytochemical markers in stage I lung cancer: Relevance to prognosis. J Clin Oncol 1997;15:2858-2865.
32. Apolinario RM, van der Valk P, de Jong JS, Deville W, van Ark-Otte J, Dingemans AM, van Mourik JC, Postmus PE, Pinedo HM, Giaccone G: Prognostic value of the expression of p53, bcl-2, and bax oncoproteins, and neovascularization in patients with radically resected non-small cell lung cancer. J Clin Oncol 1997;15:2456-2466.
33. Dworakowska D, Gozdz S, Jassem E, Badzio A, Kobierska G, Urbaniak A, Skokowski J, Damps I, Jassem J: Prognostic relevance of proliferating cell nuclear antigen and p53 expression in non-small cell lung cancer. Lung Cancer 2002;35:35-41.
34. Dworakowska D, Jassem E, Wiedorn K, Dziadziuszko R, Kobierska G, Skokowski J, Bosse A, Jassem J: p53 and mdm2 expression in NSCLC: The lack of prognostic relevance. Eur Respir J 2001;18 (suppl 33), 230s, p 1591.
35. Xu HJ, Hu SX, Benedict WF: Lack of nuclear RB protein staining in G0/middle G1 cells: Correlation to changes in total RB protein level. Oncogene 1991,6:1139-1146.